181 related articles for article (PubMed ID: 16718947)
21. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
[TBL] [Abstract][Full Text] [Related]
22. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
Zinner NR; Mattiasson A; Stanton SL
J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
[TBL] [Abstract][Full Text] [Related]
24. Comparative adherence to oxybutynin or tolterodine among older patients.
Gomes T; Juurlink DN; Mamdani MM
Eur J Clin Pharmacol; 2012 Jan; 68(1):97-9. PubMed ID: 21710237
[TBL] [Abstract][Full Text] [Related]
25. Syndrome of inappropriate antidiuretic hormone associated with tolterodine therapy.
Bryan MK; Nguyen MT; Hilas O
Consult Pharm; 2010 May; 25(5):320-2. PubMed ID: 20497930
[TBL] [Abstract][Full Text] [Related]
26. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
[TBL] [Abstract][Full Text] [Related]
27. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
29. Tolterodine use for symptoms of overactive bladder.
Ruscin JM; Morgenstern NE
Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
[TBL] [Abstract][Full Text] [Related]
30. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
Jonas U; Rackley RR
Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
[No Abstract] [Full Text] [Related]
31. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
Babu R
Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
[TBL] [Abstract][Full Text] [Related]
32. Tolterodine causes measurable restoration of urethral sensation in women with urge urinary incontinence.
Kenton K; Lowenstein L; Brubaker L
Neurourol Urodyn; 2010 Apr; 29(4):555-7. PubMed ID: 19771598
[TBL] [Abstract][Full Text] [Related]
33. Tolterodine: a clinical review.
Crandall C
J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
[TBL] [Abstract][Full Text] [Related]
34. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
[TBL] [Abstract][Full Text] [Related]
36. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
37. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).
Sussman D; Garely A
Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616
[TBL] [Abstract][Full Text] [Related]
38. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
Jacquetin B; Wyndaele J
Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):97-102. PubMed ID: 11516807
[TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
[TBL] [Abstract][Full Text] [Related]
40. [Overactive bladder. New anticholinergic drug controls urinary urge].
MMW Fortschr Med; 2004 Jul; 146(27-28):51. PubMed ID: 15526670
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]